SG11202106401UA - Estrogen receptor antagonist - Google Patents
Estrogen receptor antagonistInfo
- Publication number
- SG11202106401UA SG11202106401UA SG11202106401UA SG11202106401UA SG11202106401UA SG 11202106401U A SG11202106401U A SG 11202106401UA SG 11202106401U A SG11202106401U A SG 11202106401UA SG 11202106401U A SG11202106401U A SG 11202106401UA SG 11202106401U A SG11202106401U A SG 11202106401UA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor antagonist
- estrogen receptor
- estrogen
- antagonist
- receptor
- Prior art date
Links
- 229940102550 Estrogen receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pregnancy & Childbirth (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811545117 | 2018-12-17 | ||
CN201910611070 | 2019-07-08 | ||
CN201910877339 | 2019-09-17 | ||
PCT/CN2019/126046 WO2020125640A1 (fr) | 2018-12-17 | 2019-12-17 | Antagoniste du récepteur des œstrogènes |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106401UA true SG11202106401UA (en) | 2021-07-29 |
Family
ID=71100660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106401UA SG11202106401UA (en) | 2018-12-17 | 2019-12-17 | Estrogen receptor antagonist |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220033376A1 (fr) |
EP (1) | EP3889133A4 (fr) |
JP (1) | JP2022513942A (fr) |
KR (1) | KR20210105384A (fr) |
CN (2) | CN117430585A (fr) |
AU (1) | AU2019400398A1 (fr) |
BR (1) | BR112021011728A8 (fr) |
CA (1) | CA3122621A1 (fr) |
MX (1) | MX2021007088A (fr) |
PH (1) | PH12021551437A1 (fr) |
SG (1) | SG11202106401UA (fr) |
WO (1) | WO2020125640A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240043401A1 (en) | 2020-12-30 | 2024-02-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Salt form of tetra-substituted olefin compound, crystal, and preparation method therefor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
SG11201405918XA (en) * | 2012-03-20 | 2014-10-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
KR102664618B1 (ko) * | 2015-05-29 | 2024-05-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 사치환된 알켄 화합물 및 그의 용도 |
WO2016196342A1 (fr) * | 2015-05-29 | 2016-12-08 | Eisai R&D Management Co., Ltd. | Composés alcéniques tétrasubstitués et leur utilisation |
AU2017239348B2 (en) * | 2016-03-25 | 2020-03-12 | Luoxin Healthcare Science and Technology Development (Beijing) Ltd. | Substituted-indole compounds as estrogen receptor down-regulators |
US20190337921A1 (en) * | 2016-11-24 | 2019-11-07 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use |
-
2019
- 2019-12-17 EP EP19900858.2A patent/EP3889133A4/fr active Pending
- 2019-12-17 SG SG11202106401UA patent/SG11202106401UA/en unknown
- 2019-12-17 KR KR1020217021890A patent/KR20210105384A/ko unknown
- 2019-12-17 CA CA3122621A patent/CA3122621A1/fr active Pending
- 2019-12-17 CN CN202311221410.4A patent/CN117430585A/zh active Pending
- 2019-12-17 CN CN201980082248.8A patent/CN113166055B/zh active Active
- 2019-12-17 MX MX2021007088A patent/MX2021007088A/es unknown
- 2019-12-17 US US17/309,712 patent/US20220033376A1/en active Pending
- 2019-12-17 WO PCT/CN2019/126046 patent/WO2020125640A1/fr unknown
- 2019-12-17 AU AU2019400398A patent/AU2019400398A1/en active Pending
- 2019-12-17 JP JP2021534652A patent/JP2022513942A/ja active Pending
- 2019-12-17 BR BR112021011728A patent/BR112021011728A8/pt unknown
-
2021
- 2021-06-17 PH PH12021551437A patent/PH12021551437A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020125640A1 (fr) | 2020-06-25 |
KR20210105384A (ko) | 2021-08-26 |
AU2019400398A1 (en) | 2021-07-15 |
JP2022513942A (ja) | 2022-02-09 |
CA3122621A1 (fr) | 2020-06-25 |
EP3889133A1 (fr) | 2021-10-06 |
MX2021007088A (es) | 2021-09-08 |
PH12021551437A1 (en) | 2021-12-06 |
CN113166055B (zh) | 2023-09-08 |
CN117430585A (zh) | 2024-01-23 |
US20220033376A1 (en) | 2022-02-03 |
BR112021011728A8 (pt) | 2023-01-31 |
CN113166055A (zh) | 2021-07-23 |
BR112021011728A2 (pt) | 2021-08-31 |
EP3889133A4 (fr) | 2022-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3820873T3 (da) | Selektive østrogenreceptornedbrydere | |
ZA202003023B (en) | Benzothiophene-based selective estrogen receptor downregulators | |
IL286461A (en) | Estrogen receptor breaks down protacs | |
DK3820874T3 (da) | Selektive estrogenreceptornedbrydere | |
IL268263A (en) | Estrogen receptor modulators | |
GB201702617D0 (en) | Receptor | |
EP3703694A4 (fr) | Promédicaments antagonistes des récepteurs opioïdes | |
GB201911187D0 (en) | Receptor | |
IL280199A (en) | Receptor for VISTA | |
IL279960A (en) | P2X3 receptor antagonists | |
GB201816639D0 (en) | GLP-1 Receptor Antagonist | |
SG11202106401UA (en) | Estrogen receptor antagonist | |
EP3388423A4 (fr) | Antagoniste du récepteur nk1 | |
EP3849567A4 (fr) | Antagonistes ciblant le récepteur des oestrogènes | |
GB201910526D0 (en) | Antagonist | |
GB201909500D0 (en) | Antagonist | |
GB201812604D0 (en) | Antagonist compounds | |
GB201816650D0 (en) | GLP-1 Receptor antagonists | |
PL3611373T3 (pl) | Wspornik dla receptora wyładowania piorunowego | |
GB201817943D0 (en) | Galanin-2 receptor agonists | |
GB201701887D0 (en) | Receptor | |
GB201700926D0 (en) | Receptor |